Edition:
United Kingdom

Zosano Pharma Corp (ZSAN.OQ)

ZSAN.OQ on NASDAQ Stock Exchange Capital Market

4.49USD
3:01pm GMT
Change (% chg)

$-0.20 (-4.26%)
Prev Close
$4.69
Open
$4.84
Day's High
$4.84
Day's Low
$4.49
Volume
2,029
Avg. Vol
11,311
52-wk High
$60.00
52-wk Low
$3.63

Chart for

About

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved... (more)

Overall

Beta: --
Market Cap(Mil.): $33.27
Shares Outstanding(Mil.): 39.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Zosano Pharma Files Prospectus Related Offering 12.5 Mln Shares

* ZOSANO PHARMA CORP FILES PROSPECTUS RELATED OFFERING 12.5 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING Source text: (http://bit.ly/2EDTBag) Further company coverage:

13 Feb 2018

BRIEF-Zosano Pharma Files Prospectus Related To 10 Mln Stock Offering

* ZOSANO PHARMA CORP FILES PROSPECTUS RELATED TO OFFERING 10 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING‍​ Source text (http://bit.ly/2GUOzEr) Further company coverage:

06 Feb 2018

BRIEF-Zosano Pharma Files For Offering Of Up To $57.5 Million Shares

* ZOSANO PHARMA FILES FOR OFFERING OF UP TO $57.5 MILLION SHARES - SEC FILING Source text :[http://bit.ly/2BPJFqj] Further company coverage:

22 Dec 2017

BRIEF-Zosano Pharma Says Board To Reduce Size To Five

* ZOSANO PHARMA SAYS BOARD OF DIRECTORS ADOPTED A RESOLUTION TO REDUCE SIZE OF BOARD TO FIVE DIRECTORS - SEC FILING Source: (http://bit.ly/2j7YwDM) Further company coverage:

15 Dec 2017

BRIEF-Zosano pharma Q3 loss per share $0.20

* Zosano pharma reports third quarter 2017 financial results and operational update

09 Nov 2017

BRIEF-Zosano Pharma announces initiation of long-term safety study for M207

* Zosano Pharma announces initiation of long-term safety study for M207 as an acute treatment of migraine Source text for Eikon: Further company coverage:

08 Nov 2017

BRIEF-Zosano enters into common stock purchase agreement with Lincoln Park Capital

* Zosano enters into common stock purchase agreement with Lincoln Park Capital Source text for Eikon: Further company coverage:

20 Oct 2017

BRIEF-Zosano appoints Kenneth Greathouse to board of directors

* Zosano appoints Kenneth Greathouse to board of directors Source text for Eikon: Further company coverage:

04 Oct 2017

BRIEF-Zosano provides patent application update

* Zosano Pharma Corp - Received official written notification of an office action from U.S. patent and trademark office

26 Sep 2017

Earnings vs. Estimates